# Eric Moessinger

> Eric Moessinger is a Series B investor at +ND Capital backing Biotechnology and Health Care. See 22 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [+ND Capital](https://shizune.co/investors/profile/nd-capital)
- Location: San Francisco, United States
- Total investments: 22
- Last investment: Sep 2023
- Lead investor: 23%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eric-moessinger-320b06

Eric Moessinger is a Series B investor at +ND Capital in San Francisco focused on Biotechnology and Health Care. Eric Moessinger is based out of San Mateo, California, and is the Partner of +ND Capital and Board Member of Syndex Bio. Eric Moessinger attended the University of Florida.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 27% |
| Health Care | 4 | 18% |
| Life Science | 3 | 14% |
| Medical | 2 | 9% |
| Therapeutics | 2 | 9% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 18% |
| Series C | 3 | 14% |
| Seed | 2 | 9% |
| Series A | 1 | 5% |
| Series D | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Partillion Bioscience | Partillion Bioscience is an early-stage life science company developing a functional single-cell analysis platform to analyze and sort single cells based on secreted proteins. The platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological functions. | $5M | Seed | Sep 26, 2023 |  |
| SQZ Biotech | SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $65M | Series D | May 18, 2020 |  |
| SQZ Biotech | SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $65M | Series D | May 18, 2020 |  |
| Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M | Series C | Apr 04, 2019 |  |
| Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M | Series C | Apr 04, 2019 |  |
| Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M | Series C | Dec 19, 2018 |  |
| Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M | Series C | Dec 19, 2018 |  |
| SQZ Biotech | SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $72M | Series C | Aug 08, 2018 |  |
| SQZ Biotech | SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $72M | Series C | Aug 08, 2018 |  |
| Serotiny | Serotiny partners with leaders in the life sciences to make better therapies and tools by designing multi-domain proteins with novel functionality. They tailor protein designs for unique demands including treatment of cancers and genetic disorders. | $3M | Seed | Jul 10, 2018 |  |

10 of 22 investments shown.

## Co-investors
- [+ND Capital](https://shizune.co/investors/profile/nd-capital) — VC Fund, 12 deals together
- [NanoDimension](https://shizune.co/investors/profile/nanodimension) — VC Fund, 9 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 8 deals together
- [Paladin Capital Group](https://shizune.co/investors/profile/paladin-capital-group) — VC Fund, 8 deals together
- [Mérieux Equity Partners](https://shizune.co/investors/profile/merieux-equity-partners) — VC Fund, 6 deals together
- [Mérieux Equity Partners](https://shizune.co/investors/profile/m%C3%A9rieux-equity-partners) — VC Fund, 6 deals together

## About +ND Capital

VC Fund · San Mateo, United States

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

5 contacts available at +ND Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Aymeric Sallin | Founder and CEO | https://shizune.co/investors/profile/aymeric-sallin |
| Eric Moessinger | Partner | https://shizune.co/investors/profile/eric-moessinger |
| Jonathan Nicholson | Director | https://shizune.co/investors/profile/jonathan-nicholson |
| Kirill Kuzmichev | Principal | https://shizune.co/investors/profile/kirill-kuzmichev |
| Louis-Philippe Lalonde | Entrepreneur-In-Residence | https://shizune.co/investors/profile/louis-philippe-lalonde-fab9 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Eric Moessinger invest in?

Eric Moessinger invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eric Moessinger last invest?

The most recent investment recorded for Eric Moessinger closed in Sep 2023. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co